Liu Zheng-Hua, Wang Ping-Ping, Yan Xiao-Jing
Department of Hematology, The First Affiliated Hospital of China Medical University， Shenyang 110001, Liaoning Province, China.
Department of Hematology, The First Affiliated Hospital of China Medical University， Shenyang 110001, Liaoning Province, China,E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Feb;30(1):77-83. doi: 10.19746/j.cnki.issn.1009-2137.2022.01.013.
To analyze the expression and clinical characteristics of CD68 in bone marrow and peripheral blood of patients with acute myeloid leukemia (AML).
The expression of CD68 in bone marrow blast cells was detected by four-color flow cytometry in 50 newly diagnosed AML patients and 23 controls. The expression of CD68 in peripheral blood of 85 newly diagnosed AML patients, 29 remission AML patients and 24 controls was detected by ELISA. The correlation between the expression rate of non-M3 AML bone marrow CD68, peripheral blood CD68 concentration and white blood cell count and other clinical data was compared respectively.
The median CD68 expression rate in myeloid leukemia cells of non-M3 AML patients was 19.7%, significantly higher than control (0.2%) (P<0.001). The median concentration of non-M3 CD68 in peripheral blood was 67.97 pg/ml, significantly higher than in control (29.94 pg/ml)（P<0.01）. There was no statistically significant difference in the plasma CD68 concentration of the peripheral blood between the newly diagnosed (45.72 pg/ml) and the remission stage (55.12 pg/ml) of non-M3 AML patients by paired analysis (P>0.05). The results showed that the higher the expression rate of CD68 in bone marrow, the higher the count of white blood cells in peripheral blood, and the lower the count of hemoglobin and platelet in peripheral blood. The higher the plasma concentration of CD68 in peripheral blood, the higher the white blood cell count and the lower the complete remission rate.
The expression of CD68 both in bone marrow and peripheral blood of patients with non-M3 AML is higher than that of control group. Patients with high expression of CD68 show a low rate of complete remission, suggesting that the expression level of CD68 is correlated with treatment response.
分析急性髓系白血病（AML）患者骨髓及外周血中CD68的表达情况及临床特征。
采用四色流式细胞术检测50例初诊AML患者及23例对照者骨髓原始细胞中CD68的表达。采用酶联免疫吸附测定法（ELISA）检测85例初诊AML患者、29例缓解期AML患者及24例对照者外周血中CD68的表达。分别比较非M3型AML患者骨髓CD68表达率、外周血CD68浓度与白细胞计数等临床资料的相关性。
非M3型AML患者髓系白血病细胞中CD68表达率中位数为19.7%，显著高于对照组（0.2%）（P<0.001）。非M3型CD68外周血浓度中位数为67.97 pg/ml，显著高于对照组（29.94 pg/ml）（P<0.01）。配对分析显示，非M3型AML患者初诊时（45.72 pg/ml）与缓解期（55.12 pg/ml）外周血浆CD68浓度差异无统计学意义（P>0.05）。结果表明，骨髓中CD68表达率越高，外周血白细胞计数越高，外周血血红蛋白及血小板计数越低。外周血中CD68血浆浓度越高，白细胞计数越高，完全缓解率越低。
非M3型AML患者骨髓及外周血中CD68的表达均高于对照组。CD68高表达患者完全缓解率低，提示CD68表达水平与治疗反应相关。
